Search research articles
Contact Us
Filters
Showing results (111-120 of 148) with videos related to
Page
of 15
Sort By:
ACS Medicinal Chemistry Letters
|
March 21, 2019
Identification and Preclinical Evaluation of the Bicyclic Pyrimidine γ-Secretase Modulator BMS-932481
Kenneth M Boy, Jason M Guernon, Dmitry S Zuev, et al.
Journal of Medicinal Chemistry
|
August 18, 2016
Small Molecule Reversible Inhibitors of Bruton's Tyrosine Kinase (BTK): Structure-Activity Relationships Leading to the Identification of 7-(2-Hydroxypropan-2-yl)-4-[2-methyl-3-(4-oxo-3,4-dihydroquinazolin-3-yl)phenyl]-9H-carbazole-1-carboxamide (BMS-935177)
George V De Lucca, Qing Shi, Qingjie Liu, et al.
Journal of Medicinal Chemistry
|
October 28, 2017
Discovery of a Parenteral Small Molecule Coagulation Factor XIa Inhibitor Clinical Candidate (BMS-962212)
Donald J P Pinto, Michael J Orwat, Leon M Smith, et al.
ACS Medicinal Chemistry Letters
|
May 20, 2026
Discovery of BMS-159, an Orally Active Imidazotriazine Pan-CK2 Inhibitor for the Treatment of Cancer
Christine M Tarby, Amy Hart, Honghe Wan, et al.
Journal of Medicinal Chemistry
|
June 22, 2022
Discovery of Two Novel Antiplatelet Clinical Candidates (BMS-986120 and BMS-986141) That Antagonize Protease-Activated Receptor 4
E Scott Priestley, Jacques Banville, Daniel Deon, et al.
Journal of Medicinal Chemistry
|
October 22, 2024
Discovery and Synthesis of Heterobifunctional Degraders of Rearranged during Transfection (RET) Kinase
Jennifer X Qiao, David Williams, Patrice Gill, et al.
Medchemcomm
|
August 16, 2018
Identification of potent tricyclic prodrug S1P<sub>1</sub> receptor modulators
David Marcoux, Hai-Yun Xiao, T G Murali Dhar, et al.
ACS Medicinal Chemistry Letters
|
February 14, 2024
Discovery of Novel TLR7 Agonists as Systemic Agent for Combination With aPD1 for Use in Immuno-oncology
Yam B Poudel, Liqi He, Matthew Cox, et al.
Journal of Medicinal Chemistry
|
September 8, 2021
Discovery of Milvexian, a High-Affinity, Orally Bioavailable Inhibitor of Factor XIa in Clinical Studies for Antithrombotic Therapy
Andrew K Dilger, Kumar B Pabbisetty, James R Corte, et al.
Journal of Medicinal Chemistry
|
December 14, 2019
Potent, Orally Bioavailable, and Efficacious Macrocyclic Inhibitors of Factor XIa. Discovery of Pyridine-Based Macrocycles Possessing Phenylazole Carboxamide P1 Groups
James R Corte, Donald J P Pinto, Tianan Fang, et al.
Page
of 15
Search research articles
Search
Showing results (111-120 of 148) with videos related to
Sort By:
Page
of 15
ACS Medicinal Chemistry Letters
|
March 21, 2019
Identification and Preclinical Evaluation of the Bicyclic Pyrimidine γ-Secretase Modulator BMS-932481
Kenneth M Boy, Jason M Guernon, Dmitry S Zuev, et al.
Journal of Medicinal Chemistry
|
August 18, 2016
Small Molecule Reversible Inhibitors of Bruton's Tyrosine Kinase (BTK): Structure-Activity Relationships Leading to the Identification of 7-(2-Hydroxypropan-2-yl)-4-[2-methyl-3-(4-oxo-3,4-dihydroquinazolin-3-yl)phenyl]-9H-carbazole-1-carboxamide (BMS-935177)
George V De Lucca, Qing Shi, Qingjie Liu, et al.
Journal of Medicinal Chemistry
|
October 28, 2017
Discovery of a Parenteral Small Molecule Coagulation Factor XIa Inhibitor Clinical Candidate (BMS-962212)
Donald J P Pinto, Michael J Orwat, Leon M Smith, et al.
ACS Medicinal Chemistry Letters
|
May 20, 2026
Discovery of BMS-159, an Orally Active Imidazotriazine Pan-CK2 Inhibitor for the Treatment of Cancer
Christine M Tarby, Amy Hart, Honghe Wan, et al.
Journal of Medicinal Chemistry
|
June 22, 2022
Discovery of Two Novel Antiplatelet Clinical Candidates (BMS-986120 and BMS-986141) That Antagonize Protease-Activated Receptor 4
E Scott Priestley, Jacques Banville, Daniel Deon, et al.
Journal of Medicinal Chemistry
|
October 22, 2024
Discovery and Synthesis of Heterobifunctional Degraders of Rearranged during Transfection (RET) Kinase
Jennifer X Qiao, David Williams, Patrice Gill, et al.
Medchemcomm
|
August 16, 2018
Identification of potent tricyclic prodrug S1P<sub>1</sub> receptor modulators
David Marcoux, Hai-Yun Xiao, T G Murali Dhar, et al.
ACS Medicinal Chemistry Letters
|
February 14, 2024
Discovery of Novel TLR7 Agonists as Systemic Agent for Combination With aPD1 for Use in Immuno-oncology
Yam B Poudel, Liqi He, Matthew Cox, et al.
Journal of Medicinal Chemistry
|
September 8, 2021
Discovery of Milvexian, a High-Affinity, Orally Bioavailable Inhibitor of Factor XIa in Clinical Studies for Antithrombotic Therapy
Andrew K Dilger, Kumar B Pabbisetty, James R Corte, et al.
Journal of Medicinal Chemistry
|
December 14, 2019
Potent, Orally Bioavailable, and Efficacious Macrocyclic Inhibitors of Factor XIa. Discovery of Pyridine-Based Macrocycles Possessing Phenylazole Carboxamide P1 Groups
James R Corte, Donald J P Pinto, Tianan Fang, et al.
Page
of 15